<p>Increased <em>MCL-1</em> expression predicts poor prognosis and disease recurrence in acute myeloid leukemia</p>

作者：Xixi Li, Jing‐dong Zhou, Xiang‐mei Wen, Ting‐juan Zhang, Dehong Wu, Zhaoqun Deng, Zhihui Zhang, Xinyue Lian, Pin-fang He, Xinyu Yao, Jiang Lin, Jun Qian · 发表于：OncoTargets and Therapy · 年份：2019 · DOI：10.2147/ott.s194549 · 被引用次数：41 · 研究领域：Acute Myeloid Leukemia Research、Immune cells in cancer、Neutrophil, Myeloperoxidase and Oxidative Mechanisms

Background: Altered expression of the BCL-2 family member MCL-1 has been linked to the progression and outcome of various malignancies. Recently, MCL-1 inhibitor S63845 was reported to kill MCL-1 -dependent cancer cells and has potential value in clinical application. Purpose: Herein, we reported MCL-1 expression pattern in Chinese de novo acute myeloid leukemia (AML) and its impact on prognosis and may provide theoretical basis for AML patients using MCL-1 inhibitor in clinics. Real-time quantitative PCR was carried out to detect the transcript of MCL-1 in AML patients. Results: MCL-1 expression was significantly up-regulated in AML compared with controls ( P =0.042). We divided the patients into two groups (higher and lower expression of MCL-1 ) based on the median level. Among both non-acute promyelocytic leukemia (APL) and cytogenetically normal AML (CN-AML), patients with higher expression of MCL-1 correlated with lower complete remission (CR) rate ( P =0.031 and 0.004, respectively) and shorter overall survival (OS) time ( P =0.008 and 0.004, respectively) compared with those with lower expression of MCL-1 . Meanwhile, Cox regression analyses revealed that overexpression of MCL-1 acted as an independent risk factor for OS in non-APL patients and CN-AML patients ( P =0.011 and 0.045, respectively). In follow-up patients, MCL-1 expression level decreased after CR compared with newly diagnosis time ( P =0.020) and increased after relapse ( P =0.004). Conclusion: Our findin...